Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - ALEXION PHARMACEUTICALS, INC. | alxnex32212312020.htm |
| 10-K - 10-K - ALEXION PHARMACEUTICALS, INC. | alxn-20201231.htm |
| EX-32.1 - EX-32.1 - ALEXION PHARMACEUTICALS, INC. | alxnex32112312020.htm |
| EX-31.2 - EX-31.2 - ALEXION PHARMACEUTICALS, INC. | alxnex31212312020.htm |
| EX-31.1 - EX-31.1 - ALEXION PHARMACEUTICALS, INC. | alxnex31112312020.htm |
| EX-21.1 - EX-21.1 - ALEXION PHARMACEUTICALS, INC. | alxnex21112312020.htm |
| EX-4.2 - EX-4.2 - ALEXION PHARMACEUTICALS, INC. | alxnex4212312020.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (No. 333-240210, 333-217905, 333-205379, 333-146319, 333-139600, 333-123212, and 333-153612) and Form S-3 (No. 333-226838) of Alexion Pharmaceuticals, Inc. of our report dated February 8, 2021 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Boston, Massachusetts
February 8, 2021